Ascendis Pharma reports promising phase III data

Ascendis Pharma has released the final phase III data from its clinical studies of candidate Transcon PTH as a treatment for hypoparathyroidism, which causes cramps and muscle spasms due to low levels of calcium and PTH.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers